<DOC>
	<DOCNO>NCT02138682</DOCNO>
	<brief_summary>This investigator initiate trial design measure accuracy diagnosis Parkinson disease use DaTscan . Currently , DaTscan FDA approve measure dopamine transporter density human tissue . This measurement assist distinguish Essential Tremor Parkinsonian Syndromes ( idiopathic Parkinson disease , Progressive Supranuclear Palsy , Multi Systems Atrophy , etc ) . This study compare clinical diagnosis symptom result scan pathological diagnosis receive time death . Patients register Parkinson Research Institute 's brain donation program , receive clinical diagnosis Parkinson disease , brain scan use DaTscan , donate tissue research autopsy purpose . The hypothesis study DaTscan diagnosis Idiopathic Parkinson Disease accurately clinician .</brief_summary>
	<brief_title>Validation DaTscan Detection Parkinson Disease Related Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<criteria>age 75 old sporadic late onset Parkinson disease one variant register tissue donation program age less 75 year old mental status prevent neuroimaging transportation site inability remain `` relatively steady '' scan procedure</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>DaT-SPECT scan</keyword>
	<keyword>Parkinson 's</keyword>
	<keyword>Diagnostic</keyword>
</DOC>